Mesoblast Q1 Ryoncil Revenue Jumps 44% to US$28M; Cash Burn Falls 85%
MESO is trading near its 52-week low of $13.05 (5.4% above the low).
Summary
Mesoblast reported Q1 FY2027 Ryoncil net revenue of US$28M, up 44% year over year, and cut net operating cash spend 85% to US$2.3M, ending the quarter with US$99M in cash. The numbers are preliminary and subject to audit.
Key Events · Earnings and Guidance · MESO
-
Ryoncil Revenue Up 44% Year Over Year
Q1 FY2027 net Ryoncil revenue reached US$28M versus US$19M in the prior-year period, a 44% increase.
-
Cash Burn Cut 85% to US$2.3M
Net operating cash spend fell to US$2.3M from US$14.9M a year earlier, leaving US$99M of cash at September 30, 2026.
-
Record Monthly Patient Starts in September
September saw the highest number of new patient starts per month, following the expected July-August summer scheduling lull; the CEO cited 54 onboarded sites as the base for further adoption.
-
Preliminary Figures Subject to Audit
Management states the results are preliminary estimates and remain subject to customary closing and audit procedures.
Analysis · MESO · Life Sciences
The Ryoncil commercial launch is scaling, and the first fiscal quarter of FY2027 makes that plain: net product revenue rose 44% year over year to US$28M while net operating cash spend collapsed 85% to just US$2.3M. Growing sales against a near-breakeven cash burn is the clearest evidence yet that the company can fund operations from product revenue rather than repeated capital raises, and it leaves US$99M of cash on the balance sheet. September set a record for new patient starts, and management points to 54 onboarded sites as the base for further penetration. The figures are preliminary management estimates subject to quarter-end closing and audit procedures, so they could be revised. This follows the FY2026 results reported 2026-08-27 (US$115.2M full-year Ryoncil revenue, US$57.5M net loss) and the 2026-08-17 completion of 350-patient enrollment in the Phase 3 chronic low back pain trial, which remains the next major value inflection with top-line data expected mid-2027.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MESO was trading at $13.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $13.05 to $21.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.